SCHEMBL5384803

SCHEMBL5384803

Cc1ccc(S(=O)(=O)c2ncn(C(=O)N(C)C)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
GAA P10253 3/20 0.41
COMT P21964 3/20 0.39
DPP4 P27487 1/20 0.38
PKM P14618 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
LIPE Q05469 1/20 0.36
MEN1 O00255 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376972 0.80 ALDH1A1 (0.45) KMT2ADPP4PKMALDH1A1KDM4E
SCHEMBL5380486 0.76 DPP4 (0.42) DPP4
SCHEMBL5376408 0.76 KMT2A (0.48) KMT2AGAACOMTPKMTDP1
SCHEMBL5396559 0.74 ALDH1A1 (0.38) KMT2AGAADPP4ALDH1A1MAPT
SCHEMBL5380508 0.73 POLB (0.55) KMT2ATDP1ALDH1A1LMNAKDM4E
SCHEMBL5384749 0.72 DPP4 (0.40) DPP4
SCHEMBL5380311 0.72 DPP4 (0.43) KMT2AGAADPP4ALDH1A1LMNA
SCHEMBL5384837 0.71 KMT2A (0.41) KMT2AGAAALDH1A1LMNAKDM4E
SCHEMBL5385568 0.70 TSHR (0.44) KMT2AGAAALDH1A1MAPTHTT
SCHEMBL5371714 0.70 DPP4 (0.39) KMT2AGAADPP4TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2004-09-23 US disclosed
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI CO., LTD. (JP) 2003-03-27 US disclosed
EP-1258480-A1 Pharmaceutical use of N-Carbamoylazole derivatives Eisai Co., Ltd. (JP) 2002-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 KMT2A 2591/4885GAA 215/4885COMT 1792/4885
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 KMT2A 2591/4885GAA 215/4885COMT 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.